PMID- 20167179
OWN - NLM
STAT- MEDLINE
DCOM- 20100712
LR  - 20211020
IS  - 1932-2968 (Electronic)
IS  - 1932-2968 (Linking)
VI  - 4
IP  - 1
DP  - 2010 Jan 1
TI  - No higher dose requirements with insulin detemir than glargine in type 2 
      diabetes: a crossover, double-blind, and randomized study using continuous 
      glucose monitoring.
PG  - 151-4
AB  - BACKGROUND: In a previous publication we reported no difference in the 24-hour 
      glucose response between two basal analog insulins, detemir and glargine, when 
      taken once a day in type 2 diabetes mellitus (T2DM). We now report the dose 
      comparison observed within this randomized, double-blind, crossover study. 
      METHOD: Of 36 patients on basal insulin and other noninsulin treatments, 29 
      completed the study. Both insulins were given once a day at 8 pm and no food was 
      taken between 6 pm and the following morning. The dose was titrated daily by 
      continuous glucose monitoring (CGM) until the basal glucose (between 12 and 6 am) 
      was <120 mg/dl but not >5% of CGM readings <70 mg/dl. Subjects were then crossed 
      over to the other insulin and titrated similarly. RESULTS: Glucose goals were 
      achieved in all subjects. The mean dosage was 0.26 U/kg with very few subjects 
      requiring >0.4 U/kg. Only 2 required an absolute dose less than 10 U/day and all 
      others required more, some considerably higher. Of the 29 subjects, 7 required a 
      greater, 6 a smaller, and 16 the same dose of detemir compared to glargine. 
      CONCLUSIONS: When given once daily in T2DM and titrated using CGM to the same 
      fasting glucose, there was no difference in the glucose response between basal 
      insulins during the basal titration period (4-10 hours after injection) nor 
      during the entire 24-hour period following the injection. Further, the mean 
      dosage to achieve this glucose goal was the same with both insulins.
CI  - 2010 Diabetes Technology Society.
FAU - King, Allen B
AU  - King AB
AD  - Diabetes Care Center, Salinas, California, USA. aking@diabetescarecenter.com
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100101
PL  - United States
TA  - J Diabetes Sci Technol
JT  - Journal of diabetes science and technology
JID - 101306166
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Insulin, Long-Acting)
RN  - 2ZM8CX04RZ (Insulin Glargine)
RN  - 4FT78T86XV (Insulin Detemir)
SB  - IM
CIN - J Diabetes Sci Technol. 2010 Jan;4(1):155-7. PMID: 20167180
MH  - Aged
MH  - *Blood Glucose Self-Monitoring/methods
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Insulin/administration & dosage/*analogs & derivatives
MH  - Insulin Detemir
MH  - Insulin Glargine
MH  - Insulin, Long-Acting
MH  - Middle Aged
MH  - *Monitoring, Ambulatory/methods
PMC - PMC2825636
EDAT- 2010/02/20 06:00
MHDA- 2010/07/14 06:00
PMCR- 2011/01/01
CRDT- 2010/02/20 06:00
PHST- 2010/02/20 06:00 [entrez]
PHST- 2010/02/20 06:00 [pubmed]
PHST- 2010/07/14 06:00 [medline]
PHST- 2011/01/01 00:00 [pmc-release]
AID - dst.4.1.0151 [pii]
AID - 10.1177/193229681000400119 [doi]
PST - epublish
SO  - J Diabetes Sci Technol. 2010 Jan 1;4(1):151-4. doi: 10.1177/193229681000400119.